卵巢癌相关易感基因的研究进展  

Research progress of ovarian cancer related susceptibility genes

作　　者：吴慧 黄守国[1] WU Hui;HUANG Shouguo(Department of Obstetrics and Gynecology,Haikou Municipal Hospital Affiliated to Xiangya Medical College of Central South University,Hainan Province,Haikou 570208,China)

机构地区：[1]中南大学湘雅医学院附属海口医院妇产科,海南海口570208

出　　处：《中国医药导报》2023年第23期52-55,共4页China Medical Herald

基　　金：海南省自然科学基金资助项目(820QN424)。

摘　　要：目前卵巢癌的治疗主要局限于手术和化疗,由于缺乏早期检测手段和药物敏感性低,复发率、死亡率多年来仍居高不下。因此,开发新的治疗策略至关重要。随着基因检测技术在卵巢癌患者中的广泛应用,研究发现细胞骨髓细胞癌基因、毛细血管扩张性共济失调突变基因、转移相关基因1、乳丝氨酸蛋白酶抑制剂基因的异常改变可作为促癌或抑癌基因在卵巢癌的发生、发展及耐药中发挥重要作用。现针对上述易感基因在卵巢癌中的作用机制进行综述,为今后卵巢癌基因编辑和基因表达调节技术的应用提供一定的理论依据。At present,the treatment of ovarian cancer is mainly limited to surgery and chemotherapy.Due to the lack of early detection means and low drug sensitivity,the recurrence rate and death rate are still high for many years.Therefore,the development of new treatment strategies is critical.With the wide application of gene detection technology in ovarian cancer patients,studies have found that the abnormal changes of myeloid cell oncogenes,telangiectasia ataxia mutant genes,transfer-related genes 1,and lactoserine protease inhibitor genes can play an important role in the occurrence,development and drug resistance of ovarian cancer as cancer promotion or tumor suppressor genes.This article reviews the mechanism of action of the above susceptibility genes in ovarian cancer,and provides some theoretical basis for the application of gene editing and gene expression regulation technology in ovarian cancer in the future.

关 键 词：卵巢癌 细胞骨髓细胞癌基因 毛细血管扩张性共济失调突变基因 转移相关基因1 乳丝氨酸蛋白酶抑制剂 诊断 预后 

分 类 号：R737.31[医药卫生—肿瘤]